Drug utilisation study of upadacitinib (Rinvoq™) in Europe to evaluate the effectiveness of additional risk minimisation measures

12/02/2021
28/01/2026
EU PAS number:
EUPAS39211
Study
Ongoing
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

p20199-protocol abstract-pmos_Redacted

English (183.53 KB - PDF) View document
Updated protocol

P20-199_Protocol v2.0_Abstract_Redacted

First published: 22/02/2024
English (155.12 KB - PDF) View document
Study results
Study report
Other information